法匹拉韦在病毒感染治疗中的应用
Favipiravir in Therapy of Viral Infections.
作者信息
Łagocka Ryta, Dziedziejko Violetta, Kłos Patrycja, Pawlik Andrzej
机构信息
Department of Conservative Dentistry and Endodontics, Pomeranian Medical University, 70-204 Szczecin, Poland.
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-204 Szczecin, Poland.
出版信息
J Clin Med. 2021 Jan 13;10(2):273. doi: 10.3390/jcm10020273.
Abstract
Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved in Japan in 2014 for therapy of influenza unresponsive to standard antiviral therapies. FPV was also used in the therapy of Ebola virus disease (EVD) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, we discuss the mechanisms of action, pharmacokinetic parameters, toxicity, and adverse effects of FPV, as well as clinical studies evaluating the use of FPV in the therapy of influenza virus (IV) infection, EVD, and SARS-CoV-2 infection, along with its effectiveness in treating other human RNA infections.
摘要
法匹拉韦（FPV）是一种新型抗病毒药物，作为RNA依赖性RNA聚合酶（RdRp）的竞争性抑制剂，可阻止病毒转录和复制。2014年，FPV在日本获批用于治疗对标准抗病毒疗法无反应的流感。FPV还被用于治疗埃博拉病毒病（EVD）和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。在本综述中，我们讨论了FPV的作用机制、药代动力学参数、毒性和不良反应，以及评估FPV在治疗流感病毒（IV）感染、EVD和SARS-CoV-2感染中的应用的临床研究，及其在治疗其他人类RNA感染中的有效性。
相似文献
1
Favipiravir in Therapy of Viral Infections.法匹拉韦在病毒感染治疗中的应用
J Clin Med. 2021 Jan 13;10(2):273. doi: 10.3390/jcm10020273.
2
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.瑞德西韦是一种直接作用的抗病毒药物，能高效抑制严重急性呼吸综合征冠状病毒 2 的 RNA 依赖性 RNA 聚合酶。
J Biol Chem. 2020 May 15;295(20):6785-6797. doi: 10.1074/jbc.RA120.013679. Epub 2020 Apr 13.
3
Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico.法匹拉韦与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）、严重急性呼吸综合征冠状病毒（SARS-CoV）、中东呼吸综合征冠状病毒（MERS-CoV）及流感病毒聚合酶的详细分子相互作用的计算机模拟研究
Microorganisms. 2020 Oct 20;8(10):1610. doi: 10.3390/microorganisms8101610.
4
Favipiravir in SARS-CoV-2 Infection: Is it Worth it?法匹拉韦治疗 2019 新型冠状病毒感染：值得吗？
Comb Chem High Throughput Screen. 2022;25(14):2413-2428. doi: 10.2174/1386207325666220414111840.
5
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.法匹拉韦治疗埃博拉病毒病的实验性治疗（JIKI试验）：在几内亚进行的一项历史对照单臂概念验证试验。
PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar.
6
Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review.了解法匹拉韦（T-705）在2019年冠状病毒病中的临床应用：一项综述。
Ther Adv Infect Dis. 2021 Dec 4;8:20499361211063016. doi: 10.1177/20499361211063016. eCollection 2021 Jan-Dec.
7
Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.COVID-19 的抗病毒治疗：基于过去抗病毒和法匹拉韦经验的最佳策略推导。
Pharmacol Ther. 2022 Jul;235:108121. doi: 10.1016/j.pharmthera.2022.108121. Epub 2022 Feb 1.
8
Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs).法匹拉韦固体脂质纳米粒（SLNs）的理化特性及体外毒性/抗SARS-CoV-2活性
Pharmaceuticals (Basel). 2021 Oct 19;14(10):1059. doi: 10.3390/ph14101059.
9
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.法匹拉韦治疗新型冠状病毒肺炎的实验性治疗：一项开放标签对照研究。
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
10
Favipiravir in the Battle with Respiratory Viruses.珐匹拉韦在与呼吸道病毒的战斗中。
Mini Rev Med Chem. 2022;22(17):2224-2236. doi: 10.2174/1389557522666220218122744.
引用本文的文献
1
Novel and repurposed antiviral molecules for arbovirus infections with epidemic Potential: A systematic review.用于具有流行潜力的虫媒病毒感染的新型及重新利用的抗病毒分子：一项系统综述。
New Microbes New Infect. 2025 Jul 10;66:101614. doi: 10.1016/j.nmni.2025.101614. eCollection 2025 Aug.
2
3
Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches.抗流感病毒的策略：已批准和创新治疗方法的最新进展
Cell Mol Life Sci. 2025 Feb 13;82(1):75. doi: 10.1007/s00018-025-05611-1.
4
5-Aminopyrazole Dimerization: Cu-Promoted Switchable Synthesis of Pyrazole-Fused Pyridazines and Pyrazines via Direct Coupling of C-H/N-H, C-H/C-H, and N-H/N-H Bonds.5-氨基吡唑二聚反应：铜促进通过C-H/N-H、C-H/C-H和N-H/N-H键的直接偶联可切换合成吡唑并哒嗪和吡嗪。
Molecules. 2025 Jan 17;30(2):381. doi: 10.3390/molecules30020381.
5
Plant resources for immunonutrients and immunomodulators to combat infectious respiratory viral diseases: a review.用于对抗传染性呼吸道病毒性疾病的免疫营养物和免疫调节剂的植物资源：综述
3 Biotech. 2024 Dec;14(12):302. doi: 10.1007/s13205-024-04143-y. Epub 2024 Nov 16.
6
Investigation of substituent effects on the electronic structure and antiviral activity of favipiravir derivatives for Covid-19 treatment using DFT and molecular docking.使用 DFT 和分子对接研究取代基效应对治疗 COVID-19 的法匹拉韦衍生物的电子结构和抗病毒活性的影响。
Sci Rep. 2024 Jul 31;14(1):17697. doi: 10.1038/s41598-024-68712-0.
7
Assessment of the potential interactions between favipiravir and radiocontrast agents.法匹拉韦与放射性造影剂之间潜在相互作用的评估。
World J Radiol. 2024 May 28;16(5):128-135. doi: 10.4329/wjr.v16.i5.128.
8
Recent Advances in the Study of the Immune Escape Mechanism of SFTSV and Its Therapeutic Agents.近年来，发热伴血小板减少综合征布尼亚病毒（SFTSV）免疫逃避机制及其治疗药物的研究进展。
Viruses. 2023 Apr 10;15(4):940. doi: 10.3390/v15040940.
9
Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.基于 cheminformatics 的研究鉴定出埃博拉病毒 VP40 的潜在抑制剂。
Int J Mol Sci. 2023 Mar 27;24(7):6298. doi: 10.3390/ijms24076298.
10
The Role of Cyclodextrins in COVID-19 Therapy-A Literature Review.环糊精在 COVID-19 治疗中的作用——文献综述。
Int J Mol Sci. 2023 Feb 3;24(3):2974. doi: 10.3390/ijms24032974.
本文引用的文献
1
Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand.法匹拉韦治疗新冠肺炎的真实世界有效性及最佳剂量：泰国一项多中心观察性研究的结果
Antibiotics (Basel). 2022 Jun 15;11(6):805. doi: 10.3390/antibiotics11060805.
2
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.口服RNA依赖性RNA聚合酶抑制剂法匹拉韦在轻至中度新型冠状病毒肺炎中的疗效和安全性：一项随机、对照、开放标签、多中心3期临床试验
Int J Infect Dis. 2021 Feb;103:62-71. doi: 10.1016/j.ijid.2020.11.142. Epub 2020 Nov 16.
3
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.COVID-19 患者巴洛沙韦马立克韦和法维拉韦的临床结局和血浆浓度：一项探索性随机对照试验。
Eur J Pharm Sci. 2021 Feb 1;157:105631. doi: 10.1016/j.ejps.2020.105631. Epub 2020 Oct 25.
4
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.法维拉韦与其他抗病毒药物或 COVID-19 治疗标准药物的比较：一项快速系统评价和荟萃分析。
Virol J. 2020 Sep 24;17(1):141. doi: 10.1186/s12985-020-01412-z.
5
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.一项关于法匹拉韦早期与晚期治疗对COVID-19住院患者疗效的前瞻性、随机、开放标签试验。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01897-20.
6
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.阿维福韦治疗中度 2019 冠状病毒病（COVID-19）患者：一项 II/III 期多中心随机临床试验的中期结果。
Clin Infect Dis. 2021 Aug 2;73(3):531-534. doi: 10.1093/cid/ciaa1176.
7
Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU.非重症 COVID-19 患者在 ICU 外早期住院和早期抗病毒治疗的结果。
Turk J Med Sci. 2021 Apr 30;51(2):411-420. doi: 10.3906/sag-2006-173.
8
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.抗 SARS-CoV-2 和其他急性病毒感染的抗病毒治疗 COVID-19 的疗效和安全性：系统评价和荟萃分析。
CMAJ. 2020 Jul 6;192(27):E734-E744. doi: 10.1503/cmaj.200647. Epub 2020 Jun 3.
9
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.法匹拉韦治疗新型冠状病毒肺炎的实验性治疗：一项开放标签对照研究。
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
10
Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection.抗严重发热伴血小板减少综合征病毒感染的抗病毒药物
Front Microbiol. 2020 Feb 11;11:150. doi: 10.3389/fmicb.2020.00150. eCollection 2020.
Zotero 插件